NCT06187909

PECS II vs. MTP for Analgesia After MRM

Completed NA Results posted Last updated 21 January 2026

What this trial tests

NA trial testing PECS II BLOCK in Breast Neoplasm Female in 88 participants. Completed in 1 August 2024.

Timeline

1 January 2024

Primary endpoint
1 July 2024

1 August 2024

Quick facts

Lead sponsor	Ain Shams University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	88
Start date	1 January 2024
Primary completion	1 July 2024
Estimated completion	1 August 2024
Sites	1 location across Egypt

Drugs / interventions tested

• PECS II BLOCK — full drug profile →
• MTP BLOCK

Conditions studied

• Breast Neoplasm Female — all drugs for Breast Neoplasm Female →
• Postoperative Pain Management — all drugs for Postoperative Pain Management →

Sponsor

Ain Shams University

Who can join

Adults 40 to 65, female only, with Breast Neoplasm Female or Postoperative Pain Management. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Post-operative Pain Severity Assessed by VAS at Hour-4 Primary · will be evaluated at hour-4 postoperatively

Visual Analogue Scale is a scale for pain assessment ranging from 0 to 10 where 0 is minimum and means no pain while 10 is maximum and means maximum pain which means worse outcome

Group	Value	95% CI
MTP Block Group	1.4	± 0.6
PECS II Block Group	2.2	± 0.7

Post-operative Pain Severity Assessed by VAS on Admission to Postanesthesia Care Unit (PACU), at Hour-2, Hour-8, Hour-12, Hour-18 and Hour-24. Secondary · 24 hours postoperatively

Comparison between postoperative pain severity after 2 hours, 4 hours, 8 hours, 12 hours, 18 hours and 24 hours postoperative between both groups using visual analogue score Visual Analogue Scale is a scale for pain assessment ranging from 0 to 10 where 0 is minimum and means no pain while 10 is maximum and means maximum pain which means worse outcome

Post-operative pain severity assessed by Visual analogue scale on admission to PACU

Group	Value	95% CI
MTP Block Group	0.3	± 0.5
PECS II Block Group	0.3	± 0.5

Post-operative pain severity assessed by Visual analogue scale at 2 hours postoperatively.

Group	Value	95% CI
MTP Block Group	1.1	± 0.8
PECS II Block Group	1.4	± 0.6

Post-operative pain severity assessed by Visual analogue scale at 8 hours postoperatively.

Group	Value	95% CI
MTP Block Group	2.5	± 0.5
PECS II Block Group	3.2	± 0.6

Post-operative pain severity assessed by Visual analogue scale at 12 hours postoperatively.

Group	Value	95% CI
MTP Block Group	2.9	± 0.6
PECS II Block Group	3.2	± 0.7

Post-operative pain severity assessed by Visual analogue scale at 18 hours postoperatively.

Group	Value	95% CI
MTP Block Group	1.9	± 0.7
PECS II Block Group	2.2	± 0.5

Post-operative pain severity assessed by Visual analogue scale at 24 hours postoperatively.

Group	Value	95% CI
MTP Block Group	1.5	± 0.8
PECS II Block Group	1.7	± 0.5

Time of First Rescue Analgesia Secondary · 24 hours postoperatively

Comparison between both groups regarding the time of first needed dose of nalbuphine

Group	Value	95% CI
MTP Block Group	12.8	± 0.8
PECS II Block Group	7.9	± 1.2

Cumulative Post-operative Nalbuphine Consumption in the First 24 Hours Secondary · 24 hours postoperatively

Comparison between both groups regarding total consumed nalbuphine in first 24 hours postoperative

Group	Value	95% CI
MTP Block Group	8.3	± 2.6
PECS II Block Group	13.3	± 3.6

Incidence of Postoperative Side Effects and Complications Secondary · 24 hours postoperatively

Comparison between both groups regarding postoperative side effects and complications

Hematoma

Group	Value	95% CI
MTP Block Group	9
PECS II Block Group	12

Nausea

Group	Value	95% CI
MTP Block Group	2
PECS II Block Group	8

vomiting

Group	Value	95% CI
MTP Block Group	1
PECS II Block Group	3

pneumothorax

Group	Value	95% CI
MTP Block Group	1
PECS II Block Group	0

Adverse events — posted to ClinicalTrials.gov

Time frame: 24 hours postoperatively. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

MTP Block Group

Serious: 1/42 (2%)

Deaths: 0/42

PECS II Block Group

Serious: 0/42 (0%)

Deaths: 0/42

Serious adverse events (1 terms)

Reaction	System	MTP Block Group	PECS II Block Group
Pneumothorax	Respiratory, thoracic and mediastinal disorders	—	—

Other adverse events (3 terms — click to expand)

Reaction	System	MTP Block Group	PECS II Block Group
Hematoma	Injury, poisoning and procedural complications	—	—
Nausea	Gastrointestinal disorders	—	—
Vomiting	Gastrointestinal disorders	—	—

Most-reported serious reactions: Pneumothorax.

Data from ClinicalTrials.gov NCT06187909 adverse events section.

Sponsor's own description

This randomized controlled study aims to compare the analgesic efficacy of the ultrasound-guided modified pectoral nerve block (PECS II) and the midpoint transverse process to pleura (MTP) block in female patients undergoing modified radical mastectomy (MRM). Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS) over the first 24 hours, with additional evaluation of opioid consumption and complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.